Cambridge-based company Biogen.

Credit: AP

LISTEN: Patent Protection And Biogen’s Recent Flurry Of Lawsuits

July 11, 2017

WGBH's Morning Edition host Bob Seay spoke with Northeastern law professor and WGBH Legal Analyst Daniel Medwed to discuss the recent efforts by Biogen, a Cambridge-based leader in the life sciences field, to file a flurry of lawsuits against competitors to protect its patents related to its blockbuster multiple sclerosis drug, Tecfidera.

 


WGBH News is supported by:
Back to top